Featured News

Sanofi bolsters patient access due to COVID-19
  • New temporary access program provides eligible people experiencing financial hardship a month’s supply of certain Sanofi medicines
  • Additionally, temporary changes to patient assistance program have been made to help ease patient access

May 15, 2020

As a result of the unprecedented impact caused by COVID-19, Sanofi is helping expand access of its medicines for those with financial or insurance situations that have changed.

Sanofi’s new temporary access program provides eligible people with immediate access to a 30-day supply of their medicine as they wait for their application to the patient assistance component of the Sanofi Patient Connection program to process. People with a valid prescription for the following medicines can call an automated helpline at (855) 700-0073 to learn more and navigate program eligibility criteria. People who don’t qualify for the temporary access program will be directed to learn more about other Sanofi savings programs that may better fit their personal situation.

  • Adlyxin® (lixisenatide) injection
  • Admelog® (insulin lispro injection) 100 Units/mL
  • Apidra® (insulin glulisine injection) 100 Units/mL
  • Lantus® (insulin glargine injection) 100 Units/mL
  • Multaq® (dronedarone) tablets
  • Toujeo® (insulin glargine injection) 300 Units/mL
  • Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL

“Sanofi takes our responsibility to help people access and afford their medicines seriously and we are proud of the diverse programs we have to address those needs, including our new temporary access program designed to support people experiencing an unexpected financial challenge such as the one caused by COVID-19,” said Gustavo Pesquin, Head of North America General Medicines at Sanofi. “We are committed to ensuring that people are able to access the medicine they need, and it is our hope this new program will help ease some of the financial burdens so many are facing today.”  

Sanofi has also made some temporary changes to its patient assistance program to help people who have recently been impacted as a result of COVID-19, including:

  • Permitting early reorder of their prescription(s)
  • Expansion of acceptable documentation for proof of income 
  • Extension of its Temporary Patient Assistance Program

More information regarding the above can be obtained by calling Sanofi Patient Connection at (888) 847-4877.

Additional patient resources remain available

The new temporary access program complements Sanofi’s innovative and industry leading savings programs that have launched in recent years to help people reduce their prescription medicine costs – all of which remain available today.

  • 100% of commercially insured people are eligible for co-pay assistance programs, regardless of income or insurance plan design, which limits out-of-pocket expenses for a majority of people to $0 or $10. Programs are available for those prescribed Adlyxin, Apidra, Lantus, Multaq, Soliqua 100/33, and Toujeo.
  • 100% of uninsured people are eligible for another savings program – regardless of income level – enabling them to buy one or multiple Sanofi products (Lantus, Toujeo, Admelog, and Apidra) for a fixed price of $99 per month, for up to ten boxes of pens and/or 10 mL vials.

More information on these additional patient resources can be found on each product’s website. Additional details about Sanofi savings programs for other disease states and our commitment to ensuring affordable access of our medicines can also be found here.

Please see full Prescribing Information, including Boxed Warning for Multaq (dronedarone).